Please login to the form below

Not currently logged in
Email:
Password:

SMC

This page shows the latest SMC news and features for those working in and with pharma, biotech and healthcare.

Dismay as NICE rejects Roche’s MS drug Ocrevus

Dismay as NICE rejects Roche’s MS drug Ocrevus

Treatment deemed too costly to treat primary progressive MS

Latest news

More from news
Approximately 14 fully matching, plus 79 partially matching documents found.

Latest Intelligence

  • Patient involvement in health technology assessment Patient involvement in health technology assessment

    We have developed a Public Involvement Network (PIN) that formalises relationships with each submitting patient group through a registration process to become an SMC Patient Group Partner. ... SMC as a respected partner in developing and shaping all

  • The reality of real-world evidence The reality of real-world evidence

    Zaltrap re-submission to the Scottish Medicines Consortium (SMC) included RWE (pooled data from two open-label, single-arm studies) to demonstrate prolonged safety and QoL benefit.

  • Charting a course for expansion Charting a course for expansion

    The dossiers are going in and the conversations with NICE and the SMC are happening and we're cautiously optimistic.”.

  • Sustainable solutions Sustainable solutions

    This is often most notable when Scotland's SMC takes a different opinion on a new drug from its counterpart for England and Wales, NICE. ... Looking at rulings in the decade to 2010 it found that NICE and the SMC held the same view on the availability of

  • Case study: Treatment guidance Case study: Treatment guidance

    Although NICE and the SMC had given positive opinions, UK experience of mifamurtide was limited.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics